Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis

類似資料

• Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
  著者:: Pang, Yinuo, 等
  出版事項: (2019)
• Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials
  著者:: Suleiman, Ahmed A., 等
  出版事項: (2019)
• Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
  著者:: Witjes, Han, 等
  出版事項: (2019)
• Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
  著者:: Suleiman, Ahmed A., 等
  出版事項: (2018)
• Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients
  著者:: Khatri, Amit, 等
  出版事項: (2019)